Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02636907 · ClinicalTrials.gov registry record · Phase 2
Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT02636907 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 77 participants.
The verdict
NCT02636907, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is an open-label, phase II study of BI 695501 to assess handling experience of patients with Rheumatoid Arthritis using an autoinjector. The extension phase is to provide patients with additional exposure to BI 695501 and to enhance the safety database for this compound.
Interventions
- DRUG BI 695501 Autoinjector
- DRUG BI 695501 Prefilled syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2016-01-06 |
| Est. Completion | 2017-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02636907
The ClinicalTrials.gov registry entry for NCT02636907 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BI 695501 Autoinjector is the first listed.
NCT02636907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02636907 about?
NCT02636907 is a clinical study titled "Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe". This is an open-label, phase II study of BI 695501 to assess handling experience of patients with Rheumatoid Arthritis using an autoinjector. The extension phase is to provide patients with additional exposure to BI 695501 and to enhance the safety database for this compound.
What is the current status of trial NCT02636907?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2016-01-06. Estimated completion is 2017-06-29.
What interventions are being tested in trial NCT02636907?
The interventions under investigation include: BI 695501 Autoinjector (DRUG), BI 695501 Prefilled syringe (DRUG).
Who is sponsoring clinical trial NCT02636907?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.